Residency · Residency · Chronic Pain Management

Anticonvulsants for Neuropathic Pain

Introduction

The gabapentinoids — gabapentin and pregabalin — are first-line treatments for neuropathic pain and among the most commonly prescribed medications in chronic pain practice. Originally developed as anticonvulsants, their analgesic utility was discovered serendipitously. Understanding their unique mechanism of action, condition-specific evidence, appropriate titration schedules, and emerging concerns regarding misuse is critical for safe and effective prescribing.

Pharmacology and Mechanism of Action

Calcium Channel Alpha-2-Delta Subunit Binding

Both gabapentin and pregabalin bind to the alpha-2-delta (a2d) subunit of voltage-gated calcium channels, specifically the a2d-1 subtype. This binding reduces calcium influx at presynaptic terminals in the dorsal horn of the spinal cord and dorsal root ganglia. With less calcium entering the terminal, the release of excitatory neurotransmitters — glutamate, substance P, norepinephrine, and calcitonin gene-related peptide (CGRP) — is diminished.

A key point is that the a2d-1 subunit is upregulated in neuropathic pain states, which accounts for the selective efficacy of gabapentinoids in neuropathic versus nociceptive pain. Despite the name "gabapentin," these drugs do not act on GABA receptors and do not enhance GABAergic transmission at therapeutic concentrations.

<image>Detailed molecular diagram of a presynaptic nerve terminal at the spinal dorsal horn synapse, showing the voltage-gated calcium channel with the alpha-2-delta-1 subunit highlighted, demonstrating how gabapentinoid binding reduces calcium influx and subsequent vesicular release of glutamate and substance P into the synaptic cleft, with a comparison panel showing the upregulated state of alpha-2-delta subunits in neuropathic versus normal conditions</image>

Pharmacokinetic Differences

The pharmacokinetic profiles of gabapentin and pregabalin differ in clinically important ways. Gabapentin has dose-dependent, saturable bioavailability — 60% at 300 mg but only 33% at 1600 mg — because its absorption relies on a saturable L-amino acid transporter. Pregabalin, by contrast, achieves greater than 90% bioavailability with linear, predictable absorption through the same transporter system but without saturation. Pregabalin also reaches peak concentration faster (1-1.5 hours versus 2-3 hours for gabapentin).

Neither drug binds to plasma proteins, and both are excreted unchanged by the kidneys without hepatic metabolism, giving them clean drug interaction profiles. Both have half-lives of 5-7 hours. However, gabapentin requires slow titration over days to weeks, while pregabalin's linear pharmacokinetics allow faster titration and more predictable dose-response relationships.

Gabapentin enacarbil (Horizant) is a prodrug designed to circumvent the saturable absorption problem, offering improved bioavailability and the convenience of once- or twice-daily dosing. Both drugs require dose adjustment in renal impairment based on GFR.

Evidence for Specific Conditions

Diabetic Peripheral Neuropathy (DPN)

Both agents are considered first-line alongside duloxetine by AAN guidelines. Pregabalin is FDA-approved for DPN with an NNT of approximately 5.0 for at least 50% pain reduction at doses of 300-600 mg per day. Gabapentin has strong evidence with an NNT of approximately 5.9 at doses of 1800-3600 mg per day.

Postherpetic Neuralgia (PHN)

Both pregabalin and gabapentin are FDA-approved for PHN, with NNTs of approximately 3.9 and 4.4, respectively, for at least 50% pain reduction. Evidence supports gabapentinoids as first-line therapy alongside TCAs and topical lidocaine. Whether early initiation during acute herpes zoster reduces the incidence of PHN remains debated.

Other Neuropathic Conditions

Pregabalin shows modest benefit for central post-stroke pain and is FDA-approved for spinal cord injury pain, with gabapentin having supporting evidence for the latter as well. For trigeminal neuralgia, carbamazepine and oxcarbazepine remain first-line, with gabapentinoids serving as second-line agents. Duloxetine is preferred over gabapentinoids for chemotherapy-induced peripheral neuropathy. In radiculopathy, gabapentinoids may help the neuropathic component but do not address mechanical pain.

Conditions with Weak or No Evidence

Gabapentinoids have no significant benefit for chronic low back pain without radiculopathy. For fibromyalgia, pregabalin is FDA-approved but with modest effect sizes (NNT around 12), while gabapentin evidence is limited. Osteoarthritis is not an appropriate indication — the nociceptive mechanism does not match the drug target.

<image>Evidence heat map showing gabapentin and pregabalin efficacy across different chronic pain conditions, with rows for each condition (diabetic neuropathy, postherpetic neuralgia, spinal cord injury, fibromyalgia, radiculopathy, low back pain, osteoarthritis) and columns showing NNT values, quality of evidence grade, and FDA approval status, color coded from dark green (strong evidence) through yellow (moderate) to red (no evidence)</image>

Dose Titration Protocols

Gabapentin

The standard titration begins with 300 mg at bedtime on day one, 300 mg twice daily on day two, and 300 mg three times daily on day three. From there, the dose is increased by 300 mg per day every 3-7 days as tolerated, targeting 1800-3600 mg per day in three divided doses. The maximum is 3600 mg per day, though some guidelines suggest up to 4800 mg per day off-label. In elderly patients, slower titration starting at 100 mg at bedtime with increases of 100 mg every 3-5 days is advisable.

Pregabalin

Pregabalin starts at 75 mg twice daily or 50 mg three times daily, increasing to 150 mg twice daily after 3-7 days based on response and tolerability. The target dose is 300-600 mg per day in two divided doses, with a maximum of 600 mg per day. Some fibromyalgia guidelines cap the dose at 300 mg per day.

Renal Dosing Adjustments

For patients with a GFR of 30-60 mL/min, the dose should be reduced by 50%. At GFR 15-30 mL/min, reduce by 75%. Patients with GFR below 15 mL/min or on hemodialysis require further reduction, with a supplemental dose administered after dialysis.

Adverse Effects

The most common dose-limiting effects are CNS-related: dizziness, somnolence, cognitive impairment (often described as "brain fog"), and ataxia. Peripheral edema is dose-dependent, occurring in approximately 5-15% of patients. Weight gain averages 2-5 kg and is more pronounced with pregabalin. Visual disturbances including blurred vision and diplopia can occur.

Falls risk is a significant concern in elderly patients — gabapentinoids increase fall risk by approximately 25%. In 2019, the FDA issued a boxed warning for respiratory depression when gabapentinoids are used concurrently with opioids, benzodiazepines, or other CNS depressants. All anticonvulsants carry an FDA warning for suicidality, though the NNH is approximately 530.

Misuse and Abuse Concerns

Pregabalin is classified as a Schedule V controlled substance in the United States, and gabapentin is scheduled in several states. The prevalence of gabapentinoid misuse is estimated at 1-2% in the general population but rises to 15-22% in opioid use disorder populations. Euphoric effects occur at supratherapeutic doses, particularly with pregabalin and especially when combined with opioids. Rapid dose escalation and requests for early refills may signal misuse.

Gabapentinoid withdrawal can cause seizures, anxiety, insomnia, and pain rebound, so these drugs should be tapered over a minimum of 1-2 weeks when discontinuing. Screening for a history of substance use disorder before initiating gabapentinoid therapy is prudent, and monitoring via prescription drug monitoring programs (PDMPs) is recommended where available.

<image>Clinical monitoring flowchart for gabapentinoid prescribing, starting with patient selection criteria and substance use disorder screening, proceeding through baseline assessments (renal function, fall risk, concurrent CNS depressant medications), dose titration pathway, scheduled follow-up visits with specific monitoring parameters at each interval, and red flag indicators for potential misuse including early refill requests and rapid dose escalation</image>

Clinical Pearls

Gabapentinoids are effective for neuropathic pain but have minimal benefit for purely nociceptive pain, making proper diagnosis essential before prescribing. Pregabalin's linear pharmacokinetics provide more predictable dose-response relationships compared to gabapentin's saturable absorption. The a2d-1 subunit upregulation in neuropathic pain states explains the selectivity of these drugs for neuropathic conditions. Gabapentinoids should always be tapered when discontinuing — abrupt cessation can trigger withdrawal seizures even in non-epileptic patients. The 2019 FDA respiratory depression warning necessitates careful risk assessment before co-prescribing with opioids or benzodiazepines. When choosing between the two, gabapentin is reasonable to try first for cost reasons, with pregabalin preferred if better bioavailability or twice-daily dosing is needed.

References

1. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162-173.
2. Wiffen PJ, Derry S, Bell RF, et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017;6(6):CD007938.
3. Goodman CW, Brett AS. Gabapentin and pregabalin for pain — is increased prescribing a cause for concern? N Engl J Med. 2017;377(5):411-414.
4. Evoy KE, Morrison MD, Saklad SR. Abuse and misuse of pregabalin and gabapentin. Drugs. 2017;77(4):403-426.

Read this lecture as Markdown